Turn Therapeutics (TTRX) Cash & Equivalents (2024 - 2026)

Turn Therapeutics' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $11.2 million; the TTM figure through Mar 2026 stood at $11.2 million (changed N/A YoY), while the FY2025 annual figure was $5.1 million, up 918.72% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $11.2 million, up from $5.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $11.2 million in Q1 2026, with the low at $498286.0 in Q3 2024.
• The 3-year median for Cash & Equivalents is $3.1 million (2025), against an average of $4.1 million.
• Peak annual rise in Cash & Equivalents reached 918.72% in 2025, while the deepest fall reached 523.37% in 2025.
• Turn Therapeutics' Cash & Equivalents stood at $498286.0 in 2024, then jumped by 918.72% to $5.1 million in 2025, then surged by 120.64% to $11.2 million in 2026.
• Business Quant data shows TTRX's Cash & Equivalents at $11.2 million in Q1 2026, $5.1 million in Q4 2025, and $3.1 million in Q3 2025.